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Introduction       
 
     
      An Alzheimer’s diagnosis is an 
overwhelming and devastating 
diagnosis for both patients and 
families.  Now imagine if this diagnosis 
was made at age 55.  Instead of 
looking forward to retirement and 
grandchildren, these people are 
preparing for a debilitating disease that 
will rob them of their memory, cognitive 
and functional abilities.  Early-onset 
familial Alzheimer’s disease (EOFAD) 
affects people before the age of 65.  
Although extremely rare, some exhibit 
symptoms as early as in their 30s.  
   
     One of the things most frustrating 
about this disease is so little is known 
about its cause.  That and the fact 
there is no cure.  There is research 
which demonstrates a connection 
between three gene mutations and the 
incidence of EOFAD.   Knowledge of 
the potential cause behind their 
disease may help some patients and 
families better understand and cope 
with this disease. 
 
     EOFAD is rare.  It is estimated only 
five percent of all Alzheimer’s 
diagnoses can be attributed to early 
onset.  In 2011, the Alzheimer’s 
Association estimated 200,000 
persons were afflicted with this disease 
in the United States (Barber, 2012).  
However, these numbers include both 
familial and sporadic forms.  It is likely 
EOFAD accounts for less than one 
percent of all cases of Alzheimer’s 
disease (Orphanet, 2009).    
 
 
                          
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Cortical shrinkage (Neuroa, 2014) 
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Alzheimer’s disease is a dreadful 
and insidious disease to have 
regardless of age but it is especially 
hard when it affects individuals in the 
prime of their life.  This disease robs 
people of their lives and leaves the 
remnants for the families and loved 
ones.  Often times EOFAD is 
misdiagnosed, not recognized and 
inadequately managed.  Dementia in 
the young is overshadowed by the 
aging population (Armari, Jarmolowicz 
& Panegyres, 2013).  Because EOFAD 
is so exceptionally rare, it has not 
received much attention.  Unlike other 
diseases, it lacks the visibility, funding 
and advocacy groups.  Additionally, it 
has not been included in any clinical 
studies or drug trials (Strobel, 2014). 
 Signs and Symptoms  
      
     EOFAD is a progressive dementia that affects cognition, behavior and functional 
abilities.  EOFAD progresses the same way as late-onset Alzheimer's disease 
however it affects patients at an earlier age, has definite family history, various 
non-cognitive neurological signs and symptoms, and is thought to have a more 
aggressive course and shorter survival time (Panegyres, & Huei-Yang, 2013)     
The seven stages of Alzheimer's disease:   
Stage 1: No impairment.  No symptoms of dementia, normal function 
Stage 2:  Very mild cognitive decline.  No symptoms of dementia detected but 
person may forget familiar words or location of everyday objects. 
Stage 3:  Mild cognitive decline.  Memory or concentration problems may be 
detected. Problems may include trouble planning or organizing, greater difficulties 
performing tasks in social or work settings. 
Stage 4:  Moderate cognitive decline.  Specific symptoms can be identified such as 
forgetting recent events and/or own personal history, becoming moody or 
withdrawn, increasing difficulty with complex tasks.  
Stage 5: Moderately severe cognitive decline. Memory gaps are evident, 
assistance is needed with day to day activities.  Confusion may exist about where 
they are or what day it is, trouble with mental arithmetic.   
Stage 6:  Severe cognitive decline.  Extensive assistance is needed with daily 
activities, memory worsens, personality changes may occur. trouble remembering 
names of spouse or caregiver, changes in sleep patterns, frequent trouble with 
bowel and bladder control, may wander and become lost.   
Stage 7:  Very severe cognitive decline.  Ability to respond to environment is 
lost. Need maximum assistance with personal care, reflexes abnormal, swallowing 
impaired (Alzheimer’s Association, 2014a) 
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Gene mutation differences in EOFAD and late-onset Alzheimer's (Neuroa, 2014) 
 Underlying Pathophysiology 
     EOFAD is an inherited autosomal dominant disease.  Scientists have discovered 3 
rare deterministic genes that have been identified as a cause the disease:  amyloid 
precursor protein (APP) on chromosome 21 accounts for 10-15% of EOFAD, 
presenilin-1 (PS1) on chromosome 14 accounts for 75-80% of EOFAD, and 
presenilin-2 (PS2) on chromosome 1 accounts for <5% of EOFAD (Wu et al., 2012).  
Each of these mutations contributes to the breakdown of APP.  The result of this 
breakdown process is the formation of harmful beta-amyloid protein fragments that 
are the main components of plaques (National Institute on Aging, 2014).  The plaques 
build up and interrupt communication between neurons.  These amyloid plaques are 
a hallmark of the disease, in addition to cerebral cortical atrophy and intraneuronal 
neurofibrillary tangles (Bird, 2012).  These intraneuronal tangles cause damage to 
brain cells and synapses.  The cerebral cortex and hippocampus shrinks and the 
ventricles enlarge.         
     People who inherit an early onset Alzheimer's mutation have a nearly 100% 
chance of developing the disease.  Each child of a parent with an early-onset 
mutation has a 50/50 chance of inheriting the disease.  EOFAD is extremely rare, an 
estimated 1% or less of Alzheimer's cases are attributed these genes (Orphanet, 
2009).   
 
 
 
 
Genetic testing and counseling can be offered to the rare families that have the 
known genetic mutation for EOFAD.  However, since there are currently no treatments 
to prevent, cure or even slow the process of Alzheimer’s, this testing would have little 
to no effect on medical treatment decisions (Alzheimer’s Association, 2014b).  It 
could, however, help families make decisions about financial matters, reproduction 
and career planning (Bird, 2012).  Although not common, if the disease causing 
mutation has been identified in the family, prenatal testing can be done by DNA 
analysis of the fetal cells.  
 
 
 
 
 Significance of Pathophysiology 
     In order to treat the cognition, 
behavior and functional abilities of 
EOFAD, both pharmacologic and 
nonpharmacologic interventions are 
needed.  The top goals of treatment 
are focused on maintaining quality of 
life, ensuring a safe environment, 
maximize function in daily activities.  
Support and education for the patient 
and family is imperative.  Encourage 
the preparation of a living will and/or 
durable power of attorney for health 
care (Alzheimer’s Association, 2014c).    
     There are five FDA approved drugs 
that treat the symptoms of Alzheimer’s 
disease (Alzheimer’s Association, 
2014c):   
Generic Brand 
 
Approved for 
 
donepezil Aricept all stages 
galantamine Razadyne mild to moderate 
memantine 
Namenda 
moderate to severe 
rivastigmine Exelon all stages 
tacrine Cognex mild to moderate 
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